Quick Answer
Beam Therapeutics Inc. reported R&D Expense of $409.62 million for fiscal year 2025.
Beam Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $409.62M | +11.4% |
| 2024 | $367.56M | -16.0% |
| 2023 | $437.38M | +40.4% |
| 2022 | $311.59M | -19.5% |
| 2021 | $387.09M | +275.2% |
| 2020 | $103.18M | +88.9% |
| 2019 | $54.62M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $109.77M | +16.5% | +7.9% |
| June 30, 2025 | $101.76M | +16.9% | +3.0% |
| March 31, 2025 | $98.82M | +16.5% | +4.8% |
| September 30, 2024 | $94.26M | -5.8% | +8.3% |
| June 30, 2024 | $87.04M | -10.8% | +2.6% |
| March 31, 2024 | $84.82M | -14.9% | -15.2% |
| September 30, 2023 | $100.05M | +17.3% | +2.5% |
| June 30, 2023 | $97.61M | +30.9% | -2.0% |
- Beam Therapeutics Inc. showed an increase of +11.4% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Beam Therapeutics Inc.’s r&d expense has grown by 650.0% (from $54.62 million to $409.62 million).
- The most recent figure is from Beam Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: